華潤醫藥(03320.HK)擬收購博雅生物(300294.SZ)完成建議轉讓及表決權委託
華潤醫藥(03320.HK)公佈,於7月15日(昨日),收到深交所關於華潤醫藥收購博雅生物(300294.SZ)控股權之審覈及合規性確認,並已完成向中國結算深圳分公司申請辦理股份過戶登記手續。
根據交易文件及補充交易文件之條款及條件,博雅生物約6,933.2萬股非限售流通股股份於昨日完成轉讓予華潤醫藥控股,建議將表決權委託予華潤醫藥控股已即時生效。於完成建議轉讓及完成建議表決權委託後,華潤醫藥控股持有博雅生物之總股本約29.17%表決權。
博雅生物的主營業務爲血液製品的研發、生產及銷售,主要產品爲血液製品、糖尿病用藥、生化類用藥、醫藥經銷。此次擬收購博雅生物的控股權是華潤醫藥進入血液製品領域的重要一步,體現出集團對博雅生物血液製品平臺價值的認可,以及對未來血液製品市場的看好。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.